Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease

Bibliography

• Danaei G, Lawes CMM, Hoom SV, Global and regional mortality from ischaemic heart disease and stroke attributable to higher than optimum blood glucose concentration: comparative risk assessment. Lancet 2006;368:1651-9
   PubMed Web of Science ®Google Scholar
• Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19
   PubMed Web of Science ®Google Scholar
• Steppel JH, Horton ES. Beta-cell failure in the pathogenesis of type 2 diabetes mellitus. Curr Diabetes Rep 2004;4:169-75
   PubMedGoogle Scholar
• Kawano H, Motoyama T, Hirashima O, Hyperglycaemia rapidly suppresses flow mediated endothelium dependant vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54
   PubMed Web of Science ®Google Scholar
• Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993;36:1119-25
   PubMed Web of Science ®Google Scholar
• Nappo F, Esposito K, Cioffi M, Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002;39:1145-50
   PubMed Web of Science ®Google Scholar
• Peter R, Okosieme OE, Rees A, Owens DR. Postprandial glucose- A potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol 2009;7:68-74
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adlae AI, Neil HA, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Klein R. Hyperglycaemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD). Effects of intensive glucose lowering in type 2 diabetes. NEJM 2008;358(24):2545-59
   PubMedGoogle Scholar
• The Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEJM 2008;358(24):2560-72
   PubMedGoogle Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients. Diabetes Care 2003;26:881-5
   PubMed Web of Science ®Google Scholar
• Peter R, Luzio SD, Dunseath G, Relationship between HbA1c and indices of glucose tolerance derived from a standardized meal test in newly diagnosed treatment naïve subjects with type 2 diabetes. Diabet Med 2006;23:990-5
   PubMed Web of Science ®Google Scholar
• Peter R, Dunseath G, Luzio SD, Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA1c in subjects with type 2 diabetes. Diabet Med 2009;26:974-80
   PubMedGoogle Scholar
• Coutinho M, Gerstein HC, Wang Y, The relationship between glucose and incident cardiovascular events : a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22(2):233-40
   PubMedGoogle Scholar
• DECODE Study Group the European Diabetes Epidemiology. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2 hour diagnostic criteria. Arch Intern Med 2001;161(3):397-405
   PubMedGoogle Scholar
• de Vegt F, Dekker JM, Ruhe HG, Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31
   PubMed Web of Science ®Google Scholar
• Donahue RP, Abbott RD, Reed DM, Postchallenge glucose concentration and coronary heart disease in menof Japanese ancestry: Honolulu Heart Program. Diabetes 1987;36:689-92
   PubMed Web of Science ®Google Scholar
• Lowe LP, Liu K, Greenland P, Diabetes, asymptomatic hyperglycaemia, and 22 year mortality in black and white men: the Chicago Heart Association Detection Project in Industry study. Diabetes Care 1997;20:163-69
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Koehler C, Henkel E, Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes. Diabet Med 2000;17(12):835-40
   PubMedGoogle Scholar
• Temelkova-Kurktschiev T, Koehler C, Schaper F, Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia 1998;41:706-12
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31(12):1-11
   Google Scholar
• Butler AE, Janson J, Bonner-Weir S, Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The treat to target trial. Diabetes Care 2003;26(11):3080-6
   PubMedGoogle Scholar
• Rosenstock J, Schwartz SL, Clark CM, Basal insulin therapy in type 2 diabetes. Diabetes Care 2001;24(4):631-6
   PubMedGoogle Scholar
• Yki-Jarvinen H, Kauppinen-Mkelin R, Tiikkainen M, Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen, Dressler A, Ziemen M. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23(8):1130-6
   PubMedGoogle Scholar
• Gough SCL. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007;77:1-15
   PubMed Web of Science ®Google Scholar
• Plank J, Wutte A, Brunner G, A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002;25(11):2053-57
   PubMedGoogle Scholar
• Holman RR, Thorne KI, Farmer AJ, ; the 4-T Study group Addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes. NEJM 2007;357(17):1716-30
   PubMedGoogle Scholar
• Boehm BO, Home PD, Behrend C, Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomised trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19:393-99
   PubMed Web of Science ®Google Scholar
• Iwamoto Y. A randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes [abstract]. Diabetologia 2003; 46:(Suppl 2):A270
   Google Scholar
• McNally P, Fitch M, Nelson G. Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycaemia on biphasic insulin aspart (BIAsp 30) than on biphasic human insulin- 30 (BHI 30): data from the REACH study [abstract]. Diabetologia 2004; 47:(Suppl 1):A327
   Google Scholar
• Raskin P, Allen E, Hollander P, Initiating insulin therapy in type 2 diabetes. A comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28(2):260-5
   PubMedGoogle Scholar
• Malone JK, Bai S, Campaigne BN, Twice daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005;22:374-81
   PubMed Web of Science ®Google Scholar
• Polonsky KS, Given BD, Van Cauter E. Twenty four hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988;81:442-8
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Kopp HP, Ristic S, Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res 2004;36:188-93
   PubMed Web of Science ®Google Scholar
• Robbins DC, Beisswenger PJ, Ceriello A, Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomised, open label, parallel-group comparison. Clin Ther 2007;29(11):2349-64
   PubMedGoogle Scholar
• Kazda C, Hulstrunk H, Helsberg K, Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomised controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006;20:145-52
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Ahmann AJ, Colon G, Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents. Diabetes Care 2008;31(1):20-5
   PubMedGoogle Scholar
• Milicevic Z, Hancu N, Car N, Effect of two starting insulin regimes in patients with type 2 diabetes not controlled on a combination of oral antihyperglycaemic medications. Exp Clin Endocrinol Diabetes 2009;117:223-29
   PubMed Web of Science ®Google Scholar
• Jacober SJ, Scism-Bacon JL, Zagar AJ; the IONW study investigators. A comparison of intensive mixture therapy with basal insulin therapy in insulin naïve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006;8:448-55
   PubMed Web of Science ®Google Scholar